Herantis Pharma
1.66 EUR +1.84%Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read moreLatest research
Extensive report
Analyst
Latest videos
Financial calendar
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Skandinaviska Enskilda Banken | 18.6 % | 18.6 % |
Joensuun kauppa ja kone Oy | 9.8 % | 9.8 % |
Premium
This content is for our Premium customers only.
Insider Transactions
Insider | Date | Total value |
---|---|---|
Tone Kvåle | 25.01.2024 | 7,500EUR |
Tone Kvåle | 01.06.2022 | 7,140EUR |
Premium
This content is for our Premium customers only.
Forum updates
Income statement
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
growth-% | 150.0 % | |||||||
EBITDA | -8.5 | -9.7 | -8.1 | 0.2 | -4.9 | -5.2 | -5.6 | -5.9 |
EBIT (adj.) | -8.1 | -12.5 | -8.0 | 0.2 | -4.9 | -5.2 | -5.6 | -5.9 |
EBIT | -8.1 | -12.5 | -8.0 | 0.2 | -4.9 | -5.2 | -5.6 | -5.9 |
Profit before taxes | -8.6 | -12.8 | -9.3 | 0.3 | -4.9 | -5.2 | -5.6 | -5.9 |
Net income | -8.6 | -12.8 | -9.3 | 0.3 | -4.9 | -5.2 | -5.6 | -5.9 |
EPS (adj.) | -0.88 | -1.15 | -0.55 | 0.01 | -0.24 | -0.22 | -0.23 | -0.25 |
growth-% | -1,840.2 % | |||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Login required
This content is only available for logged in users
Profitability and return on capital
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
EBITDA-% | -213,375.0 % | -243,525.0 % | -201,825.0 % | 3,850.0 % | -48,550.5 % | -51,916.5 % | -55,529.5 % | -59,408.8 % |
EBIT-% (adj.) | -201,775.0 % | -311,525.0 % | -199,825.0 % | 3,850.0 % | -48,550.5 % | -51,916.5 % | -55,529.5 % | -59,408.8 % |
EBIT-% | -201,775.0 % | -311,525.0 % | -199,825.0 % | 3,850.0 % | -48,550.5 % | -51,916.5 % | -55,529.5 % | -59,408.8 % |
ROE | -226.6 % | -396.1 % | 1,541.2 % | 12.0 % | -182.3 % | -1,007.8 % | 235.6 % | 73.3 % |
ROI | -109.1 % | -119.5 % | -151.8 % | 3.3 % | -128.8 % | -188.8 % | -370.2 % | -2,376.4 % |
Login required
This content is only available for logged in users
Valuation
2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e | 2027e | |
---|---|---|---|---|---|---|---|---|
Share price (EUR) | 3.95 | 2.28 | 1.65 | 1.58 | 1.66 | 1.66 | 1.66 | 1.66 |
Shares | 9.8 | 11.1 | 16.9 | 20.2 | 20.2 | 23.9 | 23.9 | 23.9 |
Market cap | 38.5 | 25.4 | 27.9 | 31.8 | 33.5 | 39.6 | 39.6 | 39.6 |
Enterprise value | 32.4 | 25.1 | 26.5 | 25.3 | 33.1 | 39.4 | 45.0 | 50.9 |
EV/S | 8,098.2 | 6,281.6 | 6,613.7 | 6,335.1 | 3,310.6 | 3,944.0 | 4,499.3 | 5,093.4 |
EV/EBITDA | - | - | - | 164.5 | - | - | - | - |
EV/EBIT (adj.) | - | - | - | 164.5 | - | - | - | - |
EV/EBIT | - | - | - | 164.5 | - | - | - | - |
P/E (adj.) | - | - | - | 113.8 | - | - | - | - |
P/E | - | - | - | 113.8 | - | - | - | - |
P/B | 5.1 | - | - | 6.7 | 54.8 | 94.5 | - | - |
P/S | 9,627.7 | 6,337.6 | 6,976.2 | 7,938.4 | 3,346.7 | 3,960.9 | 3,960.9 | 3,960.9 |
Dividend yield | ||||||||
Equity ratio | 46.2 % | -14.7 % | -1.1 % | 69.9 % | 22.2 % | 15.2 % | -2,053.5 % | -4,429.8 % |
Gearing ratio | -80.6 % | 19.6 % | 2,071.4 % | -136.0 % | -59.1 % | -40.4 % | -104.9 % | -102.3 % |
Login required
This content is only available for logged in users
Quarter data
Q1/23 | Q2/23 | Q3/23 | Q4/23 | 2023 | Q1/24e | Q2/24e | Q3/24e | Q4/24e | |
---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | ||||||
EBITDA | -2.4 | 2.6 | 0.2 | -2.4 | -2.5 | ||||
EBIT | -2.4 | 2.6 | 0.2 | -2.4 | -2.5 | ||||
Profit before taxes | -1.8 | 2.1 | 0.3 | -2.4 | -2.5 | ||||
Net income | -1.8 | 2.1 | 0.3 | -2.4 | -2.5 |
Login required
This content is only available for logged in users
Herantis Pharma initiation of coverage: Early stage drug development requires good nerves
Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act (19 April 2024)
Join Inderes community
Don't miss out - create an account and get all the possible benefits